Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brazil's Chamber of Deputies, the most common co-covered peer. The tracked stories average 2 original sources each. Brazil's Senate appears in 1 tracked Biotech story from July 27, 2026.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brazil's Chamber of Deputies, the most common co-covered peer. The tracked stories average 2 original sources each. Brazil's Senate appears in 1 tracked Biotech story from July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Brazil's Senate. Shared-story counts are live from our verified record — not editorial picks.
The CEIS law provides regulatory stability and procurement incentives for domestic drug and vaccine makers, opening doors for investment in Brazil's biotech sector. It signals a long-term government commitment to reducing import reliance and fostering innovation.
Source: brazilsun.com · argentinastar.com
Brazil's Senate is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
